Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
enVVeno Medical Corporation is a clinical-stage medical device company focused on the development of implantable solutions for the treatment of chronic venous insufficiency (CVI), a condition that can lead to venous leg ulcers and significant morbidity. The company operates within the medical device and vascular health industries, targeting large unmet needs in venous disease treatment where existing therapies are limited or invasive.
The company’s primary product candidate is the VenoValve, a bioprosthetic venous valve designed to restore competency in deep venous systems of the leg. enVVeno Medical is positioned as a first-mover in the development of a surgically implanted valve specifically designed for venous disease, differentiating it from traditional compression therapies or off-label arterial valve adaptations. The company was founded in 2005 and has evolved from early-stage research into late-stage clinical development, with increasing focus on regulatory approval and commercialization in the United States.
Business Operations
enVVeno Medical’s operations are centered on research, development, and clinical validation of its proprietary venous valve technology. The company currently does not generate commercial revenue, as its lead product remains under regulatory review. Its core business activities include clinical trials, regulatory engagement with the U.S. Food and Drug Administration, manufacturing scale-up preparation, and intellectual property management related to venous valve design.
Operations are primarily U.S.-based, with clinical trial sites located in multiple domestic medical centers. The company controls proprietary biomaterial and valve-design technology used in the VenoValve system and relies on third-party manufacturers and clinical research organizations to support development activities. enVVeno Medical does not report any active joint ventures, but it maintains relationships with academic medical institutions and vascular surgeons involved in clinical studies.
Strategic Position & Investments
Strategically, enVVeno Medical is focused on achieving regulatory approval and commercial readiness for the VenoValve system, which represents its primary growth initiative. The company has invested heavily in late-stage clinical trials, including pivotal studies intended to support premarket approval submissions in the U.S. Its strategy emphasizes addressing severe CVI patients who are refractory to conservative management, a segment with limited therapeutic alternatives.
The company has not disclosed material acquisitions or a diversified investment portfolio. Its capital deployment is concentrated on internal research and development, regulatory activities, and strengthening its patent portfolio. enVVeno Medical’s technology is positioned within the emerging field of venous-specific implantable devices, which remains underpenetrated relative to arterial and cardiac valve markets.
Geographic Footprint
enVVeno Medical is headquartered in Irvine, California, and its operational footprint is primarily concentrated in the United States. Clinical trials and regulatory efforts are focused on the U.S. healthcare system, reflecting the company’s near-term commercialization strategy.
While the company has indicated long-term interest in international markets, particularly in Europe, there is limited evidence of active overseas operations or commercial infrastructure as of the most recent public disclosures. Any international expansion remains contingent on regulatory milestones and capital availability.
Leadership & Governance
enVVeno Medical is led by an executive team with experience in medical devices, cardiovascular technologies, and public company governance. The leadership emphasizes disciplined clinical development, regulatory rigor, and targeted commercialization within specialized vascular markets.
Key executives include:
- Scott M. King – President and Chief Executive Officer
- Gary L. Phillips – Chief Financial Officer
- Dr. Mark A. Wendland – Chief Medical Officer
- Richard A. Hill – Vice President of Clinical Affairs
The company is governed by a board of directors with backgrounds in medical technology, healthcare investing, and regulatory strategy, supporting management’s focus on long-term value creation through successful product approval and adoption.